Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | UNG | P13051 | 2/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL251286 | 0.85 | ALOX5 (0.52) | CA12CA1CA2CA9UNG | |
| SCHEMBL207815 | 0.85 | MAPT (0.51) | CA12CA1CA2CA9UNG | |
| SCHEMBL206623 | 0.85 | MAPT (0.51) | CA12CA1CA2CA9UNG | |
| SCHEMBL204770 | 0.83 | ALOX5 (0.67) | ALOX5MAPTNPC1MEN1KMT2A | |
| SCHEMBL206325 | 0.83 | NPC1 (0.49) | CA12CA1CA2CA9UNG | |
| SCHEMBL208382 | 0.83 | NPC1 (0.49) | CA12CA1CA2CA9UNG | |
| SCHEMBL207481 | 0.83 | ALOX5 (0.54) | ALOX5MAPTNPC1MEN1KMT2A | |
| SCHEMBL205221 | 0.82 | ALOX5 (0.69) | ALOX5MAPTNPC1MEN1KMT2A | |
| SCHEMBL249615 | 0.82 | MAPT (0.49) | CA12CA1CA2CA9ALOX5 | |
| SCHEMBL206163 | 0.81 | MEN1 (0.55) | CA12CA1CA2CA9ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | CA12 3857/4885CA1 2690/4885CA2 2057/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | CA12 3857/4885CA1 2690/4885CA2 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.